Cjc-1295 For Muscle Growth vs Tesamorelin: Literature and Handling Compared
Where Cjc-1295 For Muscle Growth and Tesamorelin overlap in the literature, and where they do not, is the substance of this reference.
Compound profiles
Cjc-1295 For Muscle Growth in the indexed record
Cjc-1295 For Muscle Growth returns 4 indexed records on PubMed, a limited record with no registered studies currently listed on ClinicalTrials.gov.
Journals represented in the current index include Am J Sports Med, J Sports Med Phys Fitness, Subst Use Misuse, spanning 2016–2026.
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — Am J Sports Med, 2026. PMID: 41476424
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions — Subst Use Misuse, 2016. PMID: 26771670
- A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review — J Sports Med Phys Fitness, 2026. PMID: 41880199
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine — Am J Sports Med, 2026. PMID: 42578445
Tesamorelin in the indexed record
Indexed output for Tesamorelin stands at 121 records, a moderate literature, alongside 24 registered studies on ClinicalTrials.gov.
Journals represented in the current index include Ann Pharmacother, BETA, Curr Opin Investig Drugs, spanning 2006–2012.
- Tesamorelin — , 2012. PMID: 31644039
- Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy — Ann Pharmacother, 2012. PMID: 22298602
- Tesamorelin, a human growth hormone releasing factor analogue — Expert Opin Investig Drugs, 2009. PMID: 19243281
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy — Drugs, 2011. PMID: 21668043
Classification and why it matters
Cjc-1295 For Muscle Growth and Tesamorelin sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for Cjc-1295 For Muscle Growth describes conditions validated for Cjc-1295 For Muscle Growth: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Tesamorelin without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Side-by-side research profile
| Parameter | Cjc-1295 For Muscle Growth | Tesamorelin |
|---|---|---|
| PubMed indexed records | 4 | 121 |
| Registered studies (ClinicalTrials.gov) | 0 | 24 |
| Literature depth | Emerging | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
How the literature differs
The indexed record is not symmetrical between these two compounds. Tesamorelin carries 117 more indexed records than Cjc-1295 For Muscle Growth, which means published methodology, characterisation data and replication attempts are more readily located for Tesamorelin. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (0 vs 24) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
What the paperwork has to show
A certificate of analysis is only meaningful when it names the lot printed on the vial. Purity by HPLC and identity by mass spectrometry answer two different questions, and a document reporting one is not evidence of the other.
Physical handling notes
Both arrive lyophilised. Standard practice keeps the unopened vial at -20°C, protected from light, and defers reconstitution until the point of use. Solution-phase stability is the limiting factor in most protocols, not powder-phase stability.
Repeated freezing and thawing is the most common avoidable source of degradation.
Frequently asked questions
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Are Cjc-1295 For Muscle Growth and Tesamorelin the same compound?
No. They are structurally distinct research compounds with separate literature records — 4 indexed records for Cjc-1295 For Muscle Growth and 121 for Tesamorelin.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Which of Cjc-1295 For Muscle Growth or Tesamorelin has more published research?
Tesamorelin, with 121 indexed PubMed records against 4.
Related references
- Tesamorelin — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.